title: mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open.
authors.affiliation: George Institute for Global Health, The University of Sydney, Sydney, Australia.
authors.forename: Meg J
authors.initials: MJ
authors.lastname: Jardine
authors.forename: Thaminda
authors.initials: T
authors.lastname: Liyanage
authors.forename: Erin
authors.initials: E
authors.lastname: Buxton
authors.forename: Vlado
authors.initials: V
authors.lastname: Perkovic
mesh_terms: D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D052177:Kidney Diseases, Cystic / Q000188:drug therapy*; D008297:Male; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy*; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus